Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.920
-0.021 (-2.25%)
Nov 21, 2024, 4:00 PM EST - Market closed
Xilio Therapeutics Analyst Ratings
Total Analysts
1
Consensus Rating
Buy
Price Target
$4.00
Upside
+334.78%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +334.78% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +660.87% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +660.87% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +986.96% | Jan 27, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +660.87% | Dec 21, 2022 |
| Raymond James | Raymond James | Buy Maintains $31 → $13 | Buy | Maintains | $31 → $13 | +1,313.04% | Nov 10, 2022 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $32 → $20 | Buy | Maintains | $32 → $20 | +2,073.91% | Aug 10, 2022 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +3,813.04% | Jan 10, 2022 |
| Raymond James | Raymond James | Buy Initiates $31 | Buy | Initiates | $31 | +3,269.57% | Nov 16, 2021 |
| Cowen & Co. | Cowen & Co. | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Nov 16, 2021 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $32 | Buy | Initiates | $32 | +3,378.26% | Nov 16, 2021 |